Abiopharma

🔍 Elliott Nicholas J (Executive)

Company: CREDIT ACCEPTANCE CORP (CACC)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 1,672 shares of Common Stock at $333.94 per share (Direct)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,569.30 | transaction_form_type: 4
• Sold 1,045 shares of Common Stock at $550.24 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,524.30 | transaction_form_type: 4 | Footnotes: F1
• Sold 80 shares of Common Stock at $551.37 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,444.30 | transaction_form_type: 4 | Footnotes: F2
• Sold 65 shares of Common Stock at $553.05 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,379.30 | transaction_form_type: 4 | Footnotes: F3
• Sold 397 shares of Common Stock at $553.9 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,982.30 | transaction_form_type: 4 | Footnotes: F4
• Sold 21 shares of Common Stock at $555.0 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,961.30 | transaction_form_type: 4 | Footnotes: F5
• Sold 51 shares of Common Stock at $557.09 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,910.30 | transaction_form_type: 4 | Footnotes: F6
• Sold 13 shares of Common Stock at $559.37 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,897.30 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-06 | Code: H | nature_of_ownership: By 401(k) Trust | shares_owned_after: 322.00 | Footnotes: F7
• Sold 1,672 shares of Employee Stock Option (right to buy) at $333.94 per share (Derivative)
  Date: 2026-05-06 | Code: M | Expires: 2026-12-30 | Exercise: 2024-12-30 | equity_swap_involved: 0 | shares_owned_after: 12,278.00 | transaction_form_type: 4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.00 to $550.89, inclusive. The reporting person undertakes to provide to Credit Acceptance Corporation, any security holder of Credit Acceptance Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.30 to $551.48, inclusive.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.53 to $553.37, inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.53 to $554.43, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.00 to $555.01, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $557.08 to $557.09, inclusive.
• F7: Held in the Credit Acceptance Stock Fund of the Credit Acceptance Corporation 401(k) Profit Sharing Plan and Trust as of May 7, 2026, according to the Plan trustee.